Article Text
Statistics from Altmetric.com
Joshua Parker’s article on green inhaler prescribing is important and timely. I agree with much of it, specifically regarding the institutional duty to make climate-friendly changes (from environmentally expensive prescriptions to ‘greener,’ similarly effective ones). The challenge, however, comes in determining how that institutional obligation impacts the rights and duties of patients. In this commentary, I want to offer a friendly alternative to Parker’s view of individual patient obligation, which I suggest is important for reasons that go beyond this one case.
Getting causal impotence right
Parker’s broad view is that, because metered-dose inhalers (MDIs) emit far more greenhouse gases (GHG) than do dry powder inhalers (DPIs), and the two are equally effective for most patients, the healthcare system should switch most patients on MDIs to DPIs, and the patients have a pro tanto duty to accept this change.1 The problem is that no individual inhaler use causes harmful climate change, and so it is difficult to explain a duty not to use MDIs. It seems that my individual behaviour ‘makes no difference’ to climate change, so familiar more principles have a difficult time justifying a prohibition of such behaviour.
Parker’s response to this worry fits into the consequentialist tradition,2 3 as he argues that each individual contribution to climate change causes some amount of ‘expected harm,’ because it contributes a little bit to future climate changes which will cause harm. And since we have a duty to minimise expected harm, we have a duty not to make such small contributions to climate change.
I think we should be sceptical of this sort of argument. It makes the most sense if we endorse a bathtub metaphor, in which the atmosphere is like a bathtub, and once it is full, every …
Footnotes
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Barriers to green inhaler prescribing: ethical issues in environmentally sustainable clinical practice
- Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England
- Towards net zero: asthma care
- Carbon footprint impact of the choice of inhalers for asthma and COPD
- Thoughtful prescription of inhaled medication has the potential to reduce inhaler-related greenhouse gas emissions by 85%
- Improving the environmental sustainability of paediatric care
- Fifteen-minute consultation: considering greener asthma treatments for children and young people
- Effects of switching from a metered dose inhaler to a dry powder inhaler on climate emissions and asthma control: post-hoc analysis
- Environmental impact of inhalers for respiratory diseases: decreasing the carbon footprint while preserving patient-tailored treatment
- The president speaks: prevention is best: lessons from protecting the ozone layer